Figure 3. Gem/nP/αCD40 therapy requires host CD40, activates antigen-presenting cells and requires Batf3⁺ dendritic cells for efficacy.

Mice were treated as described in Figure 1A.

(A, B) CD40 KO mice. (A) Left, change in tumor volume on day 24 versus day 12 (start of therapy). Right, tumor growth kinetics. (B) Tumors were analyzed on day 24 with regard to the proportions of indicated cells and ratios among live, CD45⁺ CD3⁺ cells.

(C) µMT KO mice. Left, change in tumor volume on day 24 compared to day 12. Right, tumor growth kinetics.

(D–F) Mice were treated as described in Figure 1A, and tumors were harvested on day 15 (24 hours after receiving CD40) and analyzed by flow cytometry with regards to the proportions of indicated subsets among live, CD45⁺ CD3⁻ cells. CD11c⁺ cells are also CD11b⁻ F4/80⁻.

(G) Batf3 KO mice treated as in Figure 1A. Left, the change in tumor volume on day 24 versus day 12, right, tumor growth kinetics.

Each bar represents an individual mouse, symbols indicate groups, and horizontal lines indicate mean ± SD (A, C, G) or each symbol represents an individual mouse, with mean ± SEM (B, D–F), data representative of 2–5 independent experiments with 3–10 mice/group. Statistical analysis by one-way ANOVA (A–C) or two-way ANOVA (D) with Tukey’s HSD post-test. See also Figure S4 and Table S1.